期刊文献+

他莫昔芬对肝细胞胰岛素敏感性的影响 被引量:3

Effect of Tamoxifen on Hepatic Cell Insulin Sensitivity
下载PDF
导出
摘要 背景:胰岛素抵抗是非酒精性脂肪性肝病(NAFLD)发生的中心环节.他莫昔芬可诱发肝脏脂肪变性,但该作用是否与胰岛素抵抗有关尚不清楚.目的:观察他莫昔芬对肝细胞胰岛素敏感性的影响并探讨其可能机制.方法:体外培养人正常肝细胞株L02,予不同浓度他莫昔芬干预24 h(联合或不联合抗氧化剂N-乙酰半胱氨酸),加人500 ng/ml胰岛素和11.1 mmol/L葡萄糖,以葡萄糖氧化酶-过氧化物酶(GOD-POD)法检测各组葡萄糖吸收量,同时检测细胞内谷胱甘肽(GSH)和超氧化物歧化酶(SOD)水平.结果:与空白对照组相比,1、3、5 μmol/L他莫昔芬可显著抑制L02细胞对葡萄糖的吸收(P〈0.05),作用呈浓度依赖性,并显著减低细胞内GSH和SOD水平(P〈0.05).N-乙酰半胱氨酸能改善他莫昔芬对L02细胞葡萄糖吸收的抑制作用(P〈0.05).结论:他莫昔芬能诱导肝细胞发生胰岛素抵抗,氧化应激可能参与其发生机制. Insulin resistance is the pivotal mechanism for the development of nonalcoholic fatty liver disease (NAFLD). Tamoxifen can induce hepatic steatosis, but whether this effect is associated with insulin resistance is uncertain. Aims: To investigate the effect of tamoxifen on hepatic cell insulin sensitivity and its potential mechanism. Methods: Cultured normal human hepatic cell line L02 was incubated with different dosages of tamoxifen for 24 hours in the presence or absence of antioxidant N-acetylcysteine. Then 500 ng/ml insulin and 11.1 mmol/L glucose were added to the culture media, and the absorption of glucose was measured by glucose oxidase-peroxidase (GOD-POD) method. The levels of glutathion (GSH) and superoxide dismutase (SOD) were determined simultaneously. Results: Compared with the blank controls, glucose absorption of L02 ceils was significantly reduced by 1, 3 and 5 Ixmol/L tamoxifen (P〈0.05) in a dosedependent manner, the levels of GSH and SOD were parallelly decreased (P〈0.05). The presence of N-acetylcysteine could ameliorate the inhibition of glucose absorption induced by tamoxifen (P〈0.05). Conclusions Tamoxifen can induce hepatic cell insulin resistance, and oxidative stress might be involved in its mechanism.
出处 《胃肠病学》 2010年第3期139-142,共4页 Chinese Journal of Gastroenterology
基金 上海市重点学科建设项目资助(No.Y0205)
关键词 他莫昔芬 胰岛素抗药性 氧化性应激 非酒精性脂肪性肝病 Tamoxifen Insulin Resistance Oxidative Stress Nonalcoholic Fatty Liver Disease
  • 相关文献

参考文献16

  • 1Nishino M, Hayakawa K, Nakamura Y, et al. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol, 2003, 180 (1): 129-134.
  • 2Saphner T, Triest-Robertson S, Li H, et al. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer, 2009, 115 (14):3189-3195.
  • 3杨桂枝,高小平,晏菊芳,欧可群.GOD-POD法微量化测定方法的建立及其在3T3-L1脂肪细胞和HepG2细胞糖摄取中的应用[J].四川解剖学杂志,2003,11(1):12-15. 被引量:45
  • 4Liu CL, Huang JK, Cheng SP, et al. Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anticancer Drugs, 2006, 17 (6): 709-713.
  • 5Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ, 2005, 330 (7497): 932.
  • 6Pratipanawatr W, Pratipanawatr T, Cusi K, et al. Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation. Diabetes, 2001, 50 (11): 2572-2578.
  • 7Chan TW, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clin Cancer Res, 2001, 7 (8): 2545-2554.
  • 8Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF- I R) signaling pathway in breast cancer cells. Cancer Res, 1997, 57 (13): 2606-2610.
  • 9Peyrade F, Frenay M, Etienne MC, et al. Age-related difference in tamoxifen disposition. Clin Phannacol Ther,1996, 59 (4): 401-410.
  • 10Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res, 1991, 51 (18): 4837- 4844.

共引文献44

同被引文献60

  • 1周小梅,李伟雄,周大桥,高辉,贺劲松,彭立生.脂肪肝大鼠线粒体膜流动性改变及活血化瘀法防治的实验研究[J].中西医结合肝病杂志,2005,15(2):91-93. 被引量:6
  • 2董志刚,马晓燕,宫成军,付克模.肝脂消颗粒剂对脂肪肝大鼠肝微粒体、线粒体脂质过氧化损伤的影响[J].中国中医药信息杂志,2006,13(3):33-34. 被引量:3
  • 3谢东浩,蔡宝昌,安益强,李霞,贾晓斌.柴胡皂苷类化学成分及药理作用研究进展[J].南京中医药大学学报,2007,23(1):63-65. 被引量:115
  • 4西原利治,路晓阳.药物诱发性NASH[J].日本医学介绍,2007,28(4):159-161. 被引量:5
  • 5Gouveri E,Papanas N,Maltezos E.The female breast and diabetes[J].The Breast,2011,20(3):205-211.
  • 6ZHANG PH,CHEN ZW,LYU D,et al.Increased risk of cancer in patients with type 2 diabetes mellitus:a retrospective cohort study in China[J].BMC Public Health,2012,12:567.
  • 7Ardefeldt PJ,Edirimanne S,Eslick GD.Diabetes increases the risk of breast cancer:a meta-analysis[J].Endocrine-Related Cancer,2012,19:793-803.
  • 8De Bruijn KM,Arends LR,Hansen BE,et al.Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer[J].British Journal of Surgery,2013,100:1421-1429.
  • 9Kaplan M,Pekkolay Z,Kucukoner M,et al.Type 2 diabetes mellitus and prognosis in early stage breast cancer women[J].Med Oncol,2012,29(3):1576–1580.
  • 10HOU G,ZHANG S,ZHANG X,et al.Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes[J].Breast Cancer Res Treat,2013,137(3):807-816.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部